Drug:
Reaction: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555309 |
US |
83 | 2 |
Inappropriate schedule of product administration, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 2 | 26555326 |
US |
80 | 1 |
Inappropriate schedule of product administration, Drug ineffective, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 3 | 26555418 |
US |
80 | 1 |
Inappropriate schedule of product administration, Drug ineffective, |
||||
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HCL, LOPERAMIDE HYDROCHLORIDE ORAL, |
||||
| 4 | 26555494 |
US |
||
Inappropriate schedule of product administration, |
||||
LENALIDOMIDE, |
||||
| 5 | 26555538 |
50 | ||
Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 6 | 26555642 |
US |
||
Physical product label issue, Inappropriate schedule of product administration, |
||||
GUSELKUMAB, |
||||
| 7 | 26555792 |
US |
45 | 2 |
Inappropriate schedule of product administration, Hepatic enzyme increased, Psoriasis, |
||||
GUSELKUMAB, |
||||
| 8 | 26555808 |
|||
Prostate cancer, Inappropriate schedule of product administration, Incorrect dose administered, |
||||
BIMEKIZUMAB, |
||||
| 9 | 26556054 |
US |
64 | |
Inappropriate schedule of product administration, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 10 | 26556379 |
CA |
45 | |
Blood pressure increased, Weight decreased, Blood pressure diastolic increased, Heart rate increased, Salmonellosis, Weight increased, Myalgia, Arthralgia, Therapeutic response shortened, Off label use, Off label use, Intentional product use issue, Inappropriate schedule of product administration, Off label use, Intentional product use issue, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 11 | 26556433 |
CA |
69 | |
Aphthous ulcer, Stomatitis, Glossitis, Tongue erythema, Tongue disorder, Condition aggravated, Tongue fungal infection, Interstitial lung disease, Arthralgia, Inappropriate schedule of product administration, Intentional product use issue, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BISOPROLOL FUMARATE, FUROSEMIDE, RABEPRAZOLE, RAMIPRIL, ROSUVASTATIN, LEVOTHYROXINE SODIUM, |
||||
| 12 | 26556466 |
US |
||
Investigation abnormal, Inappropriate schedule of product administration, |
||||
| 13 | 26556658 |
US |
90 | 2 |
Inappropriate schedule of product administration, |
||||
ACETAMINOPHEN, |
||||
| 14 | 26556688 |
CA |
63 | 2 |
Alopecia, Application site reaction, Chronic spontaneous urticaria, Depression, Dyspnoea, Dyspnoea exertional, Haemorrhage, Headache, Hepatic enzyme increased, Urticaria, Tachycardia, Insomnia, Intervertebral disc protrusion, Malaise, Middle insomnia, Muscular weakness, Pain, Paraesthesia, Primary biliary cholangitis, Pruritus, Scratch, Skin burning sensation, Skin lesion, Skin plaque, Spinal meningeal cyst, Stress, Erythema, Product dose omission issue, Drug ineffective, Incorrect dose administered, Inappropriate schedule of product administration, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, NICOTINE, NICOTINE POLACRILEX, NICOTINE POLACRILEX MINI, NICOTINE POLARILEX, |
||||
| 15 | 26556695 |
US |
79 | 1 |
Product distribution issue, Inappropriate schedule of product administration, |
||||
POMALIDOMIDE, |
||||
| 16 | 26556949 |
US |
49 | 2 |
Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 17 | 26557171 |
US |
46 | 1 |
Product prescribing issue, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 18 | 26557175 |
US |
9 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 19 | 26557227 |
US |
2 | |
Rheumatoid arthritis, Inappropriate schedule of product administration, |
||||
ETANERCEPT, |
||||
| 20 | 26557286 |
73 | ||
Blood pressure increased, Inappropriate schedule of product administration, Product use issue, Therapy interrupted, |
||||
LACOSAMIDE, |
||||
| 21 | 26557288 |
CA |
38 | 2 |
Ear pruritus, Inappropriate schedule of product administration, Off label use, Pruritus, Throat irritation, |
||||
RITUXIMAB, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIMENHYDRINATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE, |
||||
| 22 | 26557319 |
US |
2 | |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 23 | 26557354 |
1 | ||
Product delivery mechanism issue, Product dose omission issue, Device malfunction, Product packaging quantity issue, Inappropriate schedule of product administration, |
||||
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE, |
||||
| 24 | 26557414 |
US |
28 | 2 |
Psoriasis, Dermatitis atopic, Product dose omission issue, Product use in unapproved indication, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 25 | 26557461 |
US |
2 | |
Paranasal sinus discomfort, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 26 | 26557588 |
US |
62 | 1 |
Dermatitis atopic, Eczema, Skin exfoliation, Pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 27 | 26557595 |
US |
8 | 1 |
Incorrect dose administered, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 28 | 26557628 |
US |
52 | 2 |
Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 29 | 26557844 |
US |
50 | 2 |
Feeling hot, Inappropriate schedule of product administration, |
||||
TRALOKINUMAB-LDRM, |
||||
| 30 | 26557887 |
US |
85 | |
Headache, Inappropriate schedule of product administration, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 31 | 26557901 |
US |
71 | 2 |
Nasopharyngitis, Bronchitis, Device malfunction, Inappropriate schedule of product administration, |
||||
BENRALIZUMAB, BENRALIZUMAB, |
||||
| 32 | 26557988 |
US |
||
Inappropriate schedule of product administration, No adverse event, |
||||
| 33 | 26558280 |
2 | ||
Inappropriate schedule of product administration, Product use issue, |
||||
| 34 | 26558797 |
US |
46 | 2 |
Deafness unilateral, Foot fracture, Stress fracture, Pain, Neck pain, Back pain, Arthralgia, Arthralgia, Arthralgia, Injection site pain, Arthralgia, Fatigue, Upper-airway cough syndrome, Tinnitus, Haemochromatosis carrier, Inappropriate schedule of product administration, |
||||
ASFOTASE ALFA, |
||||
| 35 | 26558803 |
US |
2 | |
Product adhesion issue, Inappropriate schedule of product administration, |
||||
CLONIDINE, LOSARTAN POTASSIUM, LOSARTAN, METOPROLOL TARTRATE, METOPROLOL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, MAGNESIUM OXIDE, |
||||
| 36 | 26559083 |
GB |
53 | 1 |
Alcohol poisoning, Accidental overdose, Abdominal discomfort, Burns second degree, Cardiac murmur, Catarrh, Cerebrovascular accident, Confusional state, Drug ineffective, Depression, Dysgeusia, Fatigue, Eczema, Frequent bowel movements, Gingival pain, Haematochezia, Hypopnoea, Inappropriate schedule of product administration, Migraine, Headache, Nightmare, Off label use, Pain, Pain in extremity, Palpitations, Parosmia, Pulmonary embolism, Pyrexia, Rash, Rectal haemorrhage, Rhinitis, Somnolence, Steroid dependence, Stress, Swollen tongue, Systemic lupus erythematosus, Tinnitus, Tubulointerstitial nephritis, Vertigo, Weight decreased, Impaired quality of life, Loss of personal independence in daily activities, Impaired work ability, Medication error, Product use in unapproved indication, Intentional product use issue, |
||||
CANDESARTAN CILEXETIL, LATANOPROST, FESOTERODINE FUMARATE, BUDESONIDE, FELODIPINE, FELODIPINE EXTENDED-RELEASE TABLETS, ROSUVASTATIN, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, DAPAGLIFLOZIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ROSUVASTATIN, HYDROCORTISONE ACETATE, HYDROCORTISONE, VEDOLIZUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, OXYCODONE, ERGOCALCIFEROL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, WARFARIN SODIUM, WARFARIN, VEDOLIZUMAB, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, FUROSEMIDE, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ADALIMUMAB, INFLIXIMAB-DYYB, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, DESOXIMETASONE, ACETAMINOPHEN, DEXTROMETHORPHAN HBR, ACETAMINOPHEN AND DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN AND PHENYLEPRINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HBR, PRAVASTATIN SODIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, RAMIPRIL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ESOMEPRAZOLE MAGNESIUM, AMLODIPINE BESYLATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE, RIVAROXABAN, METHOTREXATE, METHOTREXATE SODIUM, TAMSULOSIN HYDROCHLORIDE, FOLIC ACID, TOFACITINIB, BISOPROLOL FUMARATE, EMPAGLIFLOZIN, LANSOPRAZOLE, NITROFURANTOIN, NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE, PREGABALIN, LATANOPROST, MINERAL OIL, NAPHAZOLINE HYDROCHLORIDE, TETRAHYDROZOLINE HYDROCHLORIDE, CAFFEINE, CALCIUM CHLORIDE INJECTION, CALCIUM CHLORIDE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, CALCIUM CARBONATE, ANTACID, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FELODIPINE, FELODIPINE EXTENDED-RELEASE TABLETS, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, DAPAGLIFLOZIN, LATANOPROST, BUDESONIDE, BUDESONIDE, BUDESONIDE, BUDESONIDE, BUDESONIDE, ROSUVASTATIN, ROSUVASTATIN, HYDROCORTISONE ACETATE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI ITCH, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, BUDESONIDE, BUDESONIDE, BUDESONIDE, BUDESONIDE, BUDESONIDE, BUDESONIDE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, HYDROCORTISONE ACETATE, DESOXIMETASONE, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, ADALIMUMAB, ADALIMUMAB, VEDOLIZUMAB, WARFARIN SODIUM, WARFARIN, OXYCODONE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, ROSUVASTATIN, |
||||
| 37 | 26559489 |
CA |
19 | 2 |
Death, Joint dislocation, Shoulder fracture, Inappropriate schedule of product administration, |
||||
FLUOXETINE HYDROCHLORIDE, FLUOXETINE, QUETIAPINE, BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE, |
||||
| 38 | 26559512 |
CN |
35 | 2 |
Liver injury, Breath sounds abnormal, Swelling face, Mouth ulceration, Oropharyngeal erythema, Inappropriate schedule of product administration, Oral mucosal discolouration, Petechiae, Pallor, |
||||
POSACONAZOLE, |
||||
| 39 | 26559659 |
|||
Product dose omission issue, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, |
||||
| 40 | 26559678 |
BR |
16 | 2 |
Crohn^s disease, Antibody test abnormal, Weight increased, Inappropriate schedule of product administration, Drug level decreased, Off label use, |
||||
INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, INFLIXIMAB, AZATHIOPRINE, |
||||
| 41 | 26559881 |
US |
64 | 2 |
Alopecia, Off label use, Inappropriate schedule of product administration, Product physical issue, |
||||
PRASTERONE, PRASTERONE, |
||||
| 42 | 26560319 |
US |
52 | 2 |
Eye pruritus, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 43 | 26560348 |
US |
7 | 1 |
Eczema, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 44 | 26560390 |
US |
66 | 2 |
Inappropriate schedule of product administration, |
||||
SARILUMAB, |
||||
| 45 | 26560434 |
US |
1 | |
Injection site pain, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 46 | 26560448 |
US |
33 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 47 | 26560502 |
56 | ||
Disability, Balance disorder, Head discomfort, Foot deformity, Movement disorder, Cough, Malaise, Gait disturbance, Insomnia, Blood pressure fluctuation, Fall, Somnolence, Dizziness, Drug ineffective, Inappropriate schedule of product administration, Therapeutic product effect variable, Incorrect dose administered by device, Treatment noncompliance, |
||||
OPICAPONE, LEVODOPA, SAFINAMIDE MESYLATE, SAFINAMIDE MESYLATE, ROTIGOTINE, |
||||
| 48 | 26560687 |
US |
||
Product contamination, Inappropriate schedule of product administration, No adverse event, |
||||
BEVACIZUMAB, |
||||
| 49 | 26560767 |
|||
Skin discolouration, Carpal tunnel syndrome, Weight increased, Illness, Stress, Sleep apnoea syndrome, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, ERGOCALCIFEROL, |
||||
| 50 | 26560943 |
EG |
69 | 2 |
Critical illness, Intentional product misuse, Inappropriate schedule of product administration, Product use issue, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 51 | 26560944 |
66 | ||
Psoriatic arthropathy, Psoriasis, Therapeutic response shortened, Inappropriate schedule of product administration, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 52 | 26561121 |
1 | ||
Inappropriate schedule of product administration, |
||||
REPOSITORY CORTICOTROPIN, |
||||
| 53 | 26561126 |
CA |
72 | 1 |
Productive cough, Heart rate increased, Infection, Inappropriate schedule of product administration, Off label use, |
||||
RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, RITUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIMENHYDRINATE, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE, |
||||
| 54 | 26561320 |
US |
69 | 2 |
Pneumonia, Inappropriate schedule of product administration, Injection site rash, Injection site pruritus, Diarrhoea, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 55 | 26561322 |
BR |
43 | 2 |
Injection site cellulitis, Inappropriate schedule of product administration, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 56 | 26561335 |
BR |
42 | 1 |
Blood glucose increased, Off label use, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 57 | 26561374 |
US |
28 | 2 |
Inappropriate schedule of product administration, |
||||
TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, TEMOZOLOMIDE, LEVETIRACETAM, LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 58 | 26561500 |
US |
89 | |
Device leakage, Inappropriate schedule of product administration, Intentional product use issue, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 59 | 26561603 |
US |
||
Inappropriate schedule of product administration, |
||||
GUSELKUMAB, |
||||
| 60 | 26561608 |
US |
10 | |
Inappropriate schedule of product administration, No adverse event, |
||||
| 61 | 26569792 |
15 | 2 | |
Rash pruritic, Rash, Inappropriate schedule of product administration, Arthralgia, |
||||
DUPILUMAB, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 62 | 26550084 |
US |
49 | 1 |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 63 | 26550126 |
US |
2 | |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 64 | 26550163 |
US |
62 | 1 |
Crohn^s disease, Neuropathy peripheral, Spinal pain, Impaired work ability, Inappropriate schedule of product administration, Product dose omission issue, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 65 | 26550180 |
US |
69 | 1 |
Product prescribing issue, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 66 | 26550237 |
US |
43 | |
Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 67 | 26550279 |
US |
2 | |
Arthritis, Adverse drug reaction, Pain, Inappropriate schedule of product administration, |
||||
ADALIMUMAB, |
||||
| 68 | 26550288 |
CN |
3 | |
Inappropriate schedule of product administration, Skin injury, Rash erythematous, Pruritus, |
||||
IBUPROFEN, |
||||
| 69 | 26550403 |
US |
68 | 2 |
Hospitalisation, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
RIPRETINIB, RIPRETINIB, |
||||
| 70 | 26550591 |
US |
72 | |
Incorrect dose administered by device, Device difficult to use, Inappropriate schedule of product administration, Therapy interrupted, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 71 | 26550655 |
US |
66 | 2 |
Crohn^s disease, Product dose omission issue, Inappropriate schedule of product administration, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, BUDESONIDE, EZETIMIBE, MONTELUKAST SODIUM, MONTELUKAST, MESALAMINE, PANTOPRAZOLE SODIUM, TIZANIDINE HYDROCHLORIDE, VITAMIN C, VITAMIN E, |
||||
| 72 | 26550767 |
US |
70 | |
Inappropriate schedule of product administration, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 73 | 26550804 |
US |
2 | |
Ocular hyperaemia, Foreign body sensation in eyes, Lacrimation increased, Vision blurred, Inappropriate schedule of product administration, Circumstance or information capable of leading to medication error, Product use issue, |
||||
PERFLUOROHEXYLOCTANE, |
||||
| 74 | 26550970 |
US |
12 | 1 |
Off label use, Inappropriate schedule of product administration, Seizure, |
||||
STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, STIRIPENTOL, CLOBAZAM, CLOBAZAM, |
||||
| 75 | 26551084 |
CA |
56 | |
Hodgkin^s disease, Hypotension, Abdominal pain upper, Urinary tract infection, Asthenia, Fatigue, Off label use, Intentional dose omission, Inappropriate schedule of product administration, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 76 | 26551197 |
US |
86 | 1 |
Death, Unresponsive to stimuli, Fall, Chills, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, CARVEDILOL, DUTASTERIDE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, GABAPENTIN, GLIPIZIDE, GLIPIZIDE-TABLETS, LATANOPROST, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PIOGLITAZONE, |
||||
| 77 | 26551207 |
US |
2 | |
Burning sensation, Pruritus, Vision blurred, Inappropriate schedule of product administration, Circumstance or information capable of leading to medication error, |
||||
| 78 | 26551278 |
US |
2 | |
Respiratory syncytial virus infection, Therapeutic product effect decreased, Inappropriate schedule of product administration, |
||||
UPADACITINIB, |
||||
| 79 | 26551290 |
CN |
57 | 2 |
Neurotoxicity, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 80 | 26551342 |
|||
Psoriasis, Inappropriate schedule of product administration, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 81 | 26551577 |
US |
53 | 2 |
Arrhythmia, Respiratory tract infection, Infection, Hypoglycaemia, Anaemia, Immune system disorder, Insurance issue, Inappropriate schedule of product administration, |
||||
HUMAN IMMUNOGLOBULIN G, |
||||
| 82 | 26551628 |
US |
84 | 1 |
Alopecia, Diarrhoea, Weight decreased, Arthralgia, Ageusia, Inappropriate schedule of product administration, Product prescribing issue, |
||||
NIVOLUMAB, CABOZANTINIB, CABOZANTINIB, FINASTERIDE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, SOTALOL HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE, ZOLPIDEM TARTRATE, |
||||
| 83 | 26551731 |
US |
2 | |
Eye pruritus, Vision blurred, Product delivery mechanism issue, Wrong technique in product usage process, Prescribed underdose, Inappropriate schedule of product administration, Product leakage, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, |
||||
| 84 | 26551753 |
BR |
2 | |
Viral infection, Inappropriate schedule of product administration, |
||||
FLUOXETINE HYDROCHLORIDE, FLUOXETINE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, OXCARBAZEPINE, |
||||
| 85 | 26551932 |
US |
1 | |
Hallucination, visual, Pruritus, Emotional distress, Pain of skin, Confusional state, Inappropriate schedule of product administration, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, ATORVASTATIN CALCIUM, MIRABEGRON, VITAMIN C, |
||||
| 86 | 26552138 |
US |
76 | 1 |
Peripheral swelling, Inappropriate schedule of product administration, Underdose, |
||||
PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, PIMAVANSERIN TARTRATE, |
||||
| 87 | 26552154 |
73 | ||
Death, Illness, Infection, Inappropriate schedule of product administration, Off label use, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 88 | 26552690 |
38 | 1 | |
Lethargy, Dizziness, Anaemia, Feeling abnormal, Fatigue, Influenza, Nasopharyngitis, Hidradenitis, Infectious mononucleosis, Inappropriate schedule of product administration, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB-RYVK, |
||||
| 89 | 26552694 |
US |
||
Inappropriate schedule of product administration, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 90 | 26552786 |
US |
2 | |
Hot flush, Inappropriate schedule of product administration, |
||||
| 91 | 26552945 |
GB |
1 | |
Colitis ulcerative, Inappropriate schedule of product administration, Wrong technique in product usage process, Incorrect dose administered, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 92 | 26552946 |
US |
73 | 1 |
Colitis ulcerative, Inappropriate schedule of product administration, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 93 | 26553034 |
US |
||
Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 94 | 26553086 |
US |
1 | |
Dizziness, Inappropriate schedule of product administration, Intentional product misuse, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 95 | 26553094 |
US |
72 | 1 |
Drug ineffective, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 96 | 26553099 |
US |
||
Drug ineffective, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 97 | 26553105 |
US |
77 | |
Incorrect dose administered, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 98 | 26553184 |
US |
1 | |
Inappropriate schedule of product administration, |
||||
DEGARELIX, |
||||
| 99 | 26553737 |
EU |
40 | 2 |
Peripheral swelling, Temperature intolerance, Angiopathy, Erythema, Pruritus, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, |
||||
| 100 | 26553863 |
US |
2 | |
Headache, Inappropriate schedule of product administration, Wrong technique in product usage process, Incorrect dose administered, Product dose omission issue, |
||||
FREMANEZUMAB-VFRM, FREMANEZUMAB-VFRM, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28